GlassScriptPhysician profile
Delaney Drew
NPI 1275238610
$702.57
in general payments reported to CMS, 2019-2025
12 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $397 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $156.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $142.07 | 2024 | Airsupra |
| Biofrontera INC. | $75.05 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $73.15 | 2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $72.45 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.33 | 2024 | Spevigo |
| Blueprint Medicines Corporation | $32.72 | 2025 | Ayvakit |
| Lilly USA, LLC | $26.34 | 2024 | Taltz |
| Incyte Corporation | $24.71 | 2025 | Opzelura |
| Amgen INC. | $17.56 | 2025 | Otezla |
| Exact Sciences Corporation | $16.96 | 2024 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $16.37 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delaney Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.